LONDON (Reuters) - GlaxoSmithKline is investing 17.5 million euros ($23.5 million) in a new venture fund to invest in drugs for rare diseases, underscoring the growing role of big drugmakers in backing start-up companies. GSK and many of its rivals are becoming more active in funding early-stage companies, reflecting both a desire to tap into smart ideas from outside their own laboratories and a scarcity of finance from many traditional venture capital firms. ...
Read the full article.
No comments:
Post a Comment